Clinical trial
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe…
NCT01580293 · Bayer, Industry · Completed
Key facts
| NCT number | NCT01580293 |
|---|---|
| Title | A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A |
| Official title | A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A |
| Acronym | PROTECT-VIII |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Biological |
| Interventions | BAY94-9027 |
| Enrollment | 145 |
| Start date | Apr 23, 2012 |
| Primary completion | Jun 13, 2014 |
| Completion | Nov 21, 2019 |
| First posted | Apr 19, 2012 |
| Last update posted | Nov 7, 2023 |
| Countries | Austria, Belgium, Canada, Colombia, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Norway and 8 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: